Fatty Acid Accumulation and Resulting PPARαActivation in Fibroblasts due to Trifunctional Protein Deficiency

Author:

Wakabayashi Masato12,Kamijo Yuji13,Nakajima Takero1,Tanaka Naoki1,Sugiyama Eiko14,Yangyang Tian1,Kimura Takefumi15,Aoyama Toshifumi1

Affiliation:

1. Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

2. Department of Pharmacy, Nagano Red Cross Hospital, Nagano 380-8582, Japan

3. Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

4. Department of Nutritional Science, Nagano Prefectural College, Nagano 380-8525, Japan

5. Department of Gastroenterology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

Abstract

To examine fatty acid accumulation and its toxic effects in cells, we analyzed skin fibroblasts from six patients with mitochondrial trifunctional protein deficiency, who had abnormalities in the second through fourth reactions in fatty acidβ-oxidation system. We found free fatty acid accumulation, enhanced three acyl-CoA dehydrogenases, catalyzing the first reaction in theβ-oxidation system and being assumed to have normal activities in these patients, and PPARαactivation that was confirmed in the experiments using MK886, a PPARαspecific antagonist and fenofibrate, a PPARαspecific agonist. These novel findings suggest that the fatty acid accumulation and the resulting PPARαactivation are major causes of the increase in theβ-oxidation ability as probable compensation for fatty acid metabolism in the patients’ fibroblasts, and that enhanced cell proliferation and increased oxidative stress due to the PPARαactivation relate to the development of specific clinical features such as hypertrophic cardiomyopathy, slight hepatomegaly, and skeletal myopathy. Additionally, significant suppression of the PPARαactivation by means of MK886 treatment is assumed to provide a new method of treating this deficiency.

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Drug Discovery

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3